Company: GLPG
Filing Date: 2025-03-27
Form Type: 20-F
Source: 0001558370-25-003806
Chunk: 387

Company: GALAPAGOS NV
Filing Date: 2025-03-27
Form: 20-F
Item: Item 16I
Chunk 387
---
201  
  Non-current contingent consideration related to milestones CellPoint      €                         20,576       20,972  
  Other non-current liabilities                                                                       13,245       10,598  
  Total other non-current liabilities                                       €                         33,821       31,570  

The carrying value of trade and other liabilities approximates their fair value.

The contingent consideration arrangement relating to the acquisition of CellPoint requires us to pay the former owners of CellPoint additional considerations up to €100.0million. This amount is due when certain sequential development (€20.0million), regulatory (€30.0million) and sales-based (€50.0million) milestones would be achieved. Total fair value at acquisition date of these milestones amounted to €20.2million at acquisition date.

The fair value measurement is based on significant inputs that are not observable in the market, which are classified as Level 3 inputs. Key assumptions in the valuation at December 31, 2022 included a discount rate of12.5%, an appropriate probability of success of reaching these milestones and expected timing of these milestones, in line with the timelines and probabilities used in our impairment test of the CAR-T business.

As per December 31, 2024 changes were made to the discount rate (13.75% at December 31, 2024 and13.72 at December 31, 2023) and the expected timing of the milestones. The only impact that was recognized compared to the date of acquisition is the discounting effect. This is recognized on the line “other financial income”. A change in probabilities of success by5 percentage points would result in a change of €2.9 million in the total contingent consideration liability on December 31, 2024. A change in the applied discount rate by1 percentage point would result in a change of€ 0.6 million in the total contingent consideration liability on December 31, 2024. A delay of one year in expected timing of the milestones would result in a decrease of €2.5 million in the total contingent consideration liability on December 31, 2024.

F-53

Table of Contents

27. Deferred income
The movement in the non-current and current deferred income is detailed in the table below.
Gilead collaboration
agreement
for filgotinib
─────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────────
(Euro, in thousands)